Abstract
This review describes our recent efforts in the development of novel therapies for cancer. Our primary approach is to design synthetic agents that antagonize the function of growth factors that are critically involved in oncogenesis and angiogenesis. We achieve this by designing synthetic molecules that can recognize the exterior surface of the growth factor and so block the interaction with its receptor tyrosine kinase. A key step is the construction of synthetic agents that contain a large (>400Å2) and functionalized surface area to recognize a complementary surface on the target growth factor. In the course of this work we have discovered a molecule, GFB-111, that binds to PDGF, prevents it from binding to its receptor tyrosine kinase, blocks PDGF-induced receptor autophosphorylation, activation of Erk1 and Erk2 kinases and DNA synthesis. The binding affinity for PDGF is high (IC50=250 nM) and selective over EGF, IGF-1, aFGF, bFGF and HRGβ. In nude mouse models GFB-111 also shows significant inhibition of tumor growth and angiogenesis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Anderson M, Ostman A, Kreysing J, Backstrom G, van de Poll M and Heldin C-H. . 1995 Growth Factors 12: 159–164.
Babine RE and Bender SL. . 1997 Chem. Rev. 97: 1359–1472.
Bach AC, Eyerman CJ, Gross JD, Bower MJ, Harlow RL, Weber PC and DeGrado WF. . 1994 J. Am. Chem. Soc. 116: 3207–3219.
Blaskovich MA, Lin Q, Delarue FL, Sun J, Park HS, Coppola D, Hamilton AD and Sebti SM. . 2000 Nature Biotechnology 18: 1065–1070.
Brandon C and Tooze J. . 1991 Introduction to Protein Structure, Garland: New York.
Campion SR and Niyogi SK. . 1994 Prog. Nucl. Acid Res. Mol. Biol. 49: 353–383.
Duan D, Pazin MJ, Fretto LJ and Williams LT. . 1991 J. Biol. Chem. 266: 413–418.
Engstom U, Engstrom A, Ernlund A, Werstermark B and Heldin C-H. . 1992 J. Biol. Chem. 267: 16581–16587.
Fenstermaker RA, Poptie E, Bonfield TL, Knauss TC, Corsillo L, Piskurich JF, Kaetzel CS, Jentoft JE, Gelfand C, DiCorleto PE and David M Kaetzel J. . 1993 J. Biol. Chem. 268: 10482–10489.
Fiona J and William GJ. . 1994 New Molecular Targets for Cancer Chemotherapy, Kerr DJ, Workman P Eds., CRC Press: Boca Raton 52.
Hamuro Y, Calama MC, Park HS and Hamilton AD. . 1997 Angew. Chemie Int. Ed. Engl. 36: 2680–2683.
Hart CE, Forstrom JW, Kelly JD, Seifert RA, Smith RA, Ross R, Murray MJ and Bowen-Pope DE. . 1988 Science 240: 1529–1531.
Hartwell LH, Szankasi P, Roberts CJ, Murray AW and Friend SH. . 1997 Science 278: 1064–1068.
Heldin C-H. . 1992 EMBO J. 11: 4251–4259.
Henriksen R, Funa K, Wilander E, Backstrom T, Ridderheim M and Oberg K. . 1993 Cancer Res. 53: 4550–4554.
Johnson A, Betsholtz C, von der Helm K, Heldin CH and Westermark B. . 1985 Proc. Natl. Acad. Sci. USA 82: 1721–1725.
LaRoclelle WJ, Pierce JH, May-Siroff M, Giese N and Aaronson SA. . 1992 J. Biol. Chem. 267: 17074–17077.
Middaugh CR, Mach H, Burke CJ, Volkin DB, Dabora JM, Tsai PK, Bruner MW, Ryan JA and Marfa KE. . 1992 Biochemistry 31: 9016–9024.
Muller YA, Li B, Christinger HW, Wells JA, Cunningham BC and de Vos AM. . 1997 Proc. Natl. Acad. Sci. USA 94: 7192–7197.
Oefner C, Arcy AD, Winkler FK, Eggimann B and Hosang M. . 1992 EMBO J. 11: 3921–3926.
Oefner C, Arey AD, Winkler FK, Eggimann B and Hosang M. . 1996 EMBO J. 11: 3921–3926.
Ostman A, Andersson M, Hellman U and Heldin C-H. . 1991 J. Biol. Chem. 266: 10073–10077.
Rockwell P and Goldstein NI. . 1995 Mol. Cell. Differ. 3: 315–335.
Sebti SM and Hamilton AD. . 2000 Expert Opinion On Investigational Drugs.
Seymour L, Dajee D and Bezwoda WR. . 1993 Breast Cancer Research and Treatment 26: 247–252.
Sun J, Blaskovich MA, Knowles D, Qian Y, Ohkanda J, Bailey RA, Hamilton AD and Sebti SM. . 1999 Cancer Res. 59: 4919–4926.
Thompson LD, Pantoliani MW and Springer BA. . 1994 Biochemistry 33: 3831–3840.
Acknowledgements
This work was supported by NIH PO1 CA78038-01A1 and United States Army grant DAMD17-99-1-9458.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sebti, S., Hamilton, A. Design of growth factor antagonists with antiangiogenic and antitumor properties. Oncogene 19, 6566–6573 (2000). https://doi.org/10.1038/sj.onc.1204121
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1204121
Keywords
This article is cited by
-
Recognition of exterior protein surfaces using artificial ligands based on calixarenes, crown ethers, and tetraphenylporphyrins
Journal of Inclusion Phenomena and Macrocyclic Chemistry (2012)
-
Is targeted chemotherapy an alternative to immunotherapy in chronic lymphocytic leukemia?
Cancer Immunology, Immunotherapy (2006)
-
Farnesyltransferase inhibitor BMS-214662 induces apoptosis in B-cell chronic lymphocytic leukemia cells
Leukemia (2004)